Publications:

TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw.

Nature Communications

Gomes, Carolina Cavalieri CC; Gayden, Tenzin T; Bajic, Andrea A; Harraz, Osama F OF; Pratt, Jonathan J; Nikbakht, Hamid H; Bareke, Eric E; Diniz, Marina Gonçalves MG; Castro, Wagner Henriques WH; St-Onge, Pascal P; Sinnett, Daniel D; Han, HyeRim H; Rivera, Barbara B; Mikael, Leonie G LG; De Jay, Nicolas N; Kleinman, Claudia L CL; Valera, Elvis Terci ET; Bassenden, Angelia V AV; Berghuis, Albert M AM; Majewski, Jacek J; Nelson, Mark T MT; Gomez, Ricardo Santiago RS; Jabado, Nada N

Publication Date: 2018-11-01

Variant appearance in text: MED16: 2400-4G>A; rs114359895

PubMed Link: 30385747

Variant Present in the following documents:

• 41467_2018_6690_MOESM8_ESM.xlsx, sheet 1

View BVdb publication page

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

Plos One

Janjigian, Yelena Y YY; Vakiani, Efsevia E; Ku, Geoffrey Y GY; Herrera, Jessica M JM; Tang, Laura H LH; Bouvier, Nancy N; Viale, Agnès A; Socci, Nicholas D ND; Capanu, Marinela M; Berger, Michael M; Ilson, David H DH

Publication Date: 2015

Variant appearance in text: rs114359895

PubMed Link: 26275293

Variant Present in the following documents:

• pone.0134731.s005.xls, sheet 1

View BVdb publication page